TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.020
-0.020 (-1.92%)
Mar 26, 2026, 2:22 PM EDT - Market open
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover TScan Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.00, which forecasts a 586.27% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $10.
Price Target: $7.00 (+586.27%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TScan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +390.20% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +586.27% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 4, 2025 |
| Needham | Needham | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +488.24% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +880.39% | May 7, 2025 |
Financial Forecast
Revenue This Year
8.64M
from 10.33M
Decreased by -16.34%
Revenue Next Year
10.35M
from 8.64M
Increased by 19.81%
EPS This Year
-0.91
from -1.00
EPS Next Year
-0.87
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 11.4M | 12.0M | |||
| Avg | 8.6M | 10.3M | |||
| Low | 2.5M | 8.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.2% | 38.4% | |||
| Avg | -16.3% | 19.8% | |||
| Low | -76.3% | 2.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.69 | -0.57 | |||
| Avg | -0.91 | -0.87 | |||
| Low | -1.45 | -1.06 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.